High socioeconomic impact on prescription behavior despite unrestricted access to disease-modifying therapies in people with multiple sclerosis

• S. Samadzadeh,
• S. Samadzadeh,
• S. Samadzadeh,
• S. Samadzadeh,
• J. Havla,
• J. Havla,
• K. Lepka,
• R. Brinks,
• S. G. Meuth,
• L. Klotz,
• P. Albrecht,
• P. Albrecht

Affiliations

S. Samadzadeh

Department of Neurology, Medical Faculty, University Hospital of Düsseldorf and Heinrich-Heine-University, Düsseldorf, Germany

S. Samadzadeh

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Berlin, Germany

S. Samadzadeh

Department of Regional Health Research and Molecular Medicine, University of Southern Denmark, Odense, Denmark

S. Samadzadeh

Department of Neurology, Slagelse Hospital, Slagelse, Denmark

J. Havla

Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität München, Munich, Germany

J. Havla

Data Integration for Future Medicine (DIFUTURE) Consortium, Ludwig-Maximilians-Universität München, Munich, Germany

K. Lepka

Department of Neurology, Medical Faculty, University Hospital of Düsseldorf and Heinrich-Heine-University, Düsseldorf, Germany

R. Brinks

Chair for Medical Biometry and Epidemiology, Witten/Herdecke University, Faculty of Health/School of Medicine, Witten, Germany

S. G. Meuth

Department of Neurology, Medical Faculty, University Hospital of Düsseldorf and Heinrich-Heine-University, Düsseldorf, Germany

L. Klotz

Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany

P. Albrecht

Department of Neurology, Medical Faculty, University Hospital of Düsseldorf and Heinrich-Heine-University, Düsseldorf, Germany

P. Albrecht

Department of Neurology, Maria Hilf Clinic, Moenchengladbach, Germany